Virus-like Particles with High-Density Antigen Coating
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The generation of antibodies is hindered by the poor incorporation of antigens of interest into virus-like particles (VLPs) in vitro, and there is a need for novel approaches to enhance the immunogenicity of HIV vaccines, particularly in eliciting neutralizing antibodies against the complex HIV envelope glycoprotein (Env).
Innovation Solution
The development of fusion proteins comprising a polypeptide of interest, a transmembrane domain, and an HIV gag polypeptide, which allows for membrane localization and increased surface density of gp41, improving the spatial presentation of antigens and enhancing immunogenic responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antigens are incorporated into VLPs using conventional methods, then VLPs can be produced, but the incorporation efficiency is poor and immunogenicity is limited
Solution Approach 1:
The patent merges the antigen of interest with the HIV gag polypeptide through fusion protein construction. The antigen is covalently linked to the gag protein, ensuring that when gag self-assembles into VLPs, the antigen is incorporated into the particle structure. This merging approach resolves the contradiction by making antigen incorporation an intrinsic part of the VLP formation process rather than a separate step, thereby improving both incorporation efficiency and immunogenicity
Solution Approach 2:
The HIV gag polypeptide acts as an intermediary that facilitates antigen incorporation into VLPs. The gag protein provides the self-assembly capability and structural framework, while the fused antigen becomes part of this assembly process. This intermediary approach allows efficient antigen incorporation without requiring direct manipulation of the antigen alone, resolving the manufacturing efficiency issue while maintaining high immunogenicity
2Reliability
If the surface density of gp41 is increased to improve antigen presentation, then immunogenicity is enhanced, but the complexity of protein design increases
Solution Approach 1:
The patent changes the parameter of surface density by fusing the antigen to the gag polypeptide in specific stoichiometric ratios. By controlling the molar ratio of antigen to gag during expression, the invention achieves optimal surface density of antigen on VLPs. This parameter change approach enhances antigen presentation capability without requiring complex multi-component protein designs, as the density control is achieved through simple expression ratio adjustment
Solution Approach 2:
The HIV gag polypeptide serves multiple functions: it provides the structural framework for VLP formation, facilitates self-assembly into particles, and when fused with antigen, enables high-density antigen presentation. This multi-functionality of the gag backbone reduces overall design complexity compared to creating separate structural and presentation components, as one protein (gag fusion) accomplishes multiple roles
Data Source
AI summary
The invention relates to a fusion protein comprising a polypeptide of interest, a transmembrane domain and an HIV gag polypeptide, or their functionally equivalent variants. The invention also relates to the polynucleotides, vectors, host cells and virus-like particles expressing or presenting said fusion proteins and to the pharmaceutical, immunogenic or vaccines composition containing said fusion proteins, polynucleotides, vectors, host cells and virus-like particles and their use in human and veterinary medicine.